Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 3/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
| ▸ | MMP12 | P39900 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 2/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15422786 | 0.80 | ALDH1A1 (0.43) | MMP2PTGS2SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL10158 | 0.75 | MMP9 (0.52) | MMP2MMP8PTGS2MMP9 | |
| SCHEMBL15422342 | 0.72 | MMP2 (0.56) | MMP2MMP8MMP12PTGS2SMN1; SMN2 | |
| SCHEMBL15453839 | 0.70 | MMP2 (0.39) | MMP2RAB9ANPC1MMP9 | |
| SCHEMBL5861 | 0.69 | FFAR1 (0.56) | SMN1; SMN2RAB9ANPC1MAPTALDH1A1 | |
| SCHEMBL15453769 | 0.68 | CA2 (0.44) | MMP2PTGS2MMP9MEN1KMT2A | |
| SCHEMBL8473505 | 0.67 | PTGS2 (0.59) | PTGS2SMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL9461597 | 0.66 | NOTUM (0.49) | SMN1; SMN2RAB9ANPC1LMNANOTUM | |
| SCHEMBL14753038 | 0.66 | RAB9A (0.57) | SMN1; SMN2RAB9ANPC1LMNANOTUM | |
| SCHEMBL11965520 | 0.66 | MEN1 (0.59) | PTGS2SMN1; SMN2RAB9ANPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748466-B2 | Isoxazole derivatives useful as antibacterial agents | PFIZER INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-20140024690-A1 | Isoxazole Derivatives Useful As Antibacterial Agents | PFIZER INC. (US) | 2014-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024690-A1 | Isoxazole Derivatives Useful As Antibacterial Agents | HAX1, PRXL2A, PRDX1 | MMP2 240/4885MMP8 132/4885MMP12 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.